在这项临床试验中,旨在评估BCMA-CD19 cCAR-T疗法治疗系统性红斑狼疮/狼疮性肾炎患者身上的疗效与安全性。11例活检证实活动性疾病(III-V类)且对至少两种疗法反应不足的狼疮性肾炎患者随后被纳入研究,并在2022年6月至2023年2月期间...
CD19-BCMA双靶点CAR(abv。cCAR)能够通过在B细胞上的CD19和在浆细胞上的BCMA(CD269)双重靶向,大幅降低供体特异性抗体水平,.这种双重作用可能是治疗自身免疫的理想选择,因为以前单独使用抗B细胞治疗和抗CD20抗体利妥昔单抗等策略的临床研究令人失望。虽然CD19 CAR T细胞治疗改善了狼疮小鼠模型的结局,但只有在疾病早...
在这项临床试验中,旨在评估BCMA-CD19 cCAR-T疗法治疗系统性红斑狼疮/狼疮性肾炎患者身上的疗效与安全性。11例活检证实活动性疾病(III-V类)且对至少两种疗法反应不足的狼疮性肾炎患者随后被纳入研究,并在2022年6月至2023年2月期间接受治疗。 结果显示,所有接受目标剂量的狼疮患者在接受cCAR-T治疗3个月后,自身抗...
在这项临床试验中,旨在评估BCMA-CD19 cCAR-T疗法治疗系统性红斑狼疮/狼疮性肾炎患者身上的疗效与安全性。11例活检证实活动性疾病(III-V类)且对至少两种疗法反应不足的狼疮性肾炎患者随后被纳入研究,并在2022年6月至2023年2月期间接受治疗。 结果显示,所有接受目标剂量的狼疮患者在接受cCAR-T治疗3个月后,自身抗...
cCAR targets the "root cause" of DSA production, B cells and plasma/long-lived plasma cells, and thus may achieve desensitization through a dual reset of humoral and B cell immune system. Aims: We present the safety and efficacy of cCAR, which targets antibody- producing "root cause", B...
T cells from peripheral blood obtained via apheresis were transfected to create cCAR. Cessation of all SLE medications (immunosuppressants, hydroxychloroquine, steroids and biologics) prior to conditioning and monitored after cCAR. IVIG prn per investigator discretion. Baseline Characteristics : 10 LN ...
We constructed a BCMA-CD19 cCAR, which is a 2-unit CAR composed of a complete BCMA-CAR fused to a complete CD19-CAR by a self-cleaving P2A peptide, enabling independent expression of both CAR receptors separately on the T-cell surface. We then assessed the functional activity of cCAR...
Complete recovery of B cells was seen in 2–6 months post-cCAR. Mean SLE Disease Activity Index 2000 reduced from 10.6 (baseline) to 2.7 (3 months), and renal function significantly improved in 10 LN patients ≤90 days post-cCAR. cCAR T therapy was well tolerant with mild cytokine-...